Tissue Regeneration Therapeutics Inc. (TRT) is a progressive biotechnology company with a focus on the commercial development of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology. We achieve this by providing license opportunities to collaborating partner companies in the regenerative therapeutics industry.
TRT has discovered the world’s richest source of mesenchymal stem cells (MSCs) with potent regenerative, angiogenic, anti-inflammatory and immuno-regulatory properties. Unique advantages of the TRT platform HUCPVC technology are founded on the highly enriched source of these very important cells compared to other tissue sources. Specifically, HUCPVCs represent high cell yields at harvest from tissue normally discarded at birth; high frequencies of mesenchymal stem cells within the harvested population, their increased biological potential compared to cells derived from adult tissue, and their inexhaustible supply.
TRT is the first company in the world to have issued and allowed patents in US and Europe for extraction of these unique cells from umbilical cord tissue. Our license to CReATe Cord Blood Bank has resulted in the provision of these services to the Canadian public for over three years, making both TRT and CreATe leaders in the worldwide stem cell community.
In addition to the HUCPVC product lines, TRT’s wholly owned subsidiary, BoneTec Corporation, has developed a biodegradable, fully resorbable and osteoconductive scaffold, OsteoScaf™, to be used in healing tissue defects.
Tissue Regeneration Therapeutics Inc. is a Canadian Controlled Private Corporation (CCPC) biotechnology company founded in 2004 on the research and intellectual property of Dr. JE Davies and his research team at the Institute of Biomaterials and Biomedical Engineering, University of Toronto (U of T).